Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,699.38
(
1.01%
)
US TECH 100
23,919.20
(
-0.40%
)
Dow Jones
46,946.41
(
0.83%
)
Brent Oil
100.92
(
2.66%
)
Bitcoin
74,063.90
(
-1.04%
)
News Focus
News Focus
Post# of 257250
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: rwdm post# 99895

Tuesday, 07/27/2010 4:41:54 PM

Tuesday, July 27, 2010 4:41:54 PM

Post# of 257250

Can you imagine that FDA's demand for a complicated molecule such as Copaxone would be less (without bioequivalence) than for a simple compound such as aspirin?

The FDA sometimes grants a waiver of the bioequivalence requirement for generic drugs that are injected.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now